Author

Isabel Redondo 1

1 Eli Lilly and Co

EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL

Silvio Danese, Axel Dignass, Katsuyoshi Matsuoka, Marc Ferrante, Millie Long, Isabel Redondo, Theresa Hunter Gibble, Richard Moses, Nathan Morris, Xingyuan Li, Catherine Milch, Maria T. Abreu

EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL

Isabel Redondo, Brian Feagan, Remo Panaccione, Christian Selinger, Trevor Lissoos, Vipin Arora, Milan Lukas, Katsuyoshi Matsuoka, Toshifumi Hibi

EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS

Fernando Magro, Rish Pai, Taku Kobayashi, Vipul Jairath, Florian Rieder, Isabel Redondo, Trevor Lissoos, Nathan Morris, Mingyang Shan, Laurent Peyrin-Biroulet

SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL

Axel Dignass, Silvio Danese, Katsuyoshi Matsuoka, Marc Ferrante, Millie Long, Isabel Redondo, Theresa Hunter Gibble, Richard Moses, Xingyuan Li, Nathan Morris, Catherine Milch, Maria T. Abreu

THE EFFECT OF MIRIKIZUMAB ON FECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PHASE 3 STUDIES OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Britta Siegmund, Bruce E. Sands, Karen Hamrick Samaan, Xingyuan Li, Nathan Morris, Theresa Hunter Gibble, Isabel Redondo, Trevor Lissoos, Geert R. D'Haens

Item 1 - 5 / 5
1